MacroGenics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Rockville MD United States (2000)

Organization Overview

First Clinical Trial
2004
NCT00101972
First Marketed Drug
2020
margetuximab (Margenza)
First NDA Approval
2020
margetuximab (Margenza)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MacroGenics | MacroGenics Inc. | MACROGENICS INC | MacroGenics, Incorporated